{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:39:56Z","timestamp":1787647196785,"version":"build-2736575974"},"reference-count":21,"publisher":"The Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Calcimimetics increase the sensitivity of the calcium-sensing receptor (CaR) to circulating serum calcium, reducing the secretion of PTH and the serum calcium concentration. We evaluated the calcimimetic cinacalcet, a novel therapy for the management of primary hyperparathyroidism. In this randomized, double-blind, dose-finding study, patients (n = 22) with primary hyperparathyroidism were given cinacalcet (30, 40, or 50 mg) or placebo twice daily for 15 d and observed for an additional 7 d. Serum calcium, plasma PTH, and 24-h and fasting urine calcium were measured. Baseline mean serum calcium was 10.6 mg\/dl for the combined cinacalcet-treated patients (normal range, 8.4\u201310.3 mg\/dl), compared with 10.4 mg\/dl for the placebo group. Mean PTH at baseline was 102 pg\/ml (normal range, 10\u201365 pg\/ml) for the combined cinacalcet-treated patients, compared with 100 pg\/ml in the placebo group. Serum calcium normalized after the second dose on d 1 and remained normal through d 15 in all cinacalcet dose groups. Maximum decreases in PTH of over 50% occurred 2\u20134 h after dosing in all cinacalcet-treated groups. The fasting and 24-h urine calcium to creatinine ratios were similar in the cinacalcet and placebo groups. This study demonstrates that cinacalcet safely normalized serum calcium and lowered PTH concentrations without increasing urinary calcium excretion in the study subjects, indicating the potential benefit of cinacalcet as a medical treatment for primary hyperparathyroidism.<\/jats:p>","DOI":"10.1210\/jc.2002-021597","type":"journal-article","created":{"date-parts":[[2003,12,11]],"date-time":"2003-12-11T17:23:51Z","timestamp":1071163431000},"page":"5644-5649","source":"Crossref","is-referenced-by-count":211,"title":["The Calcimimetic Cinacalcet Normalizes Serum Calcium in Subjects with Primary Hyperparathyroidism"],"prefix":"10.1210","volume":"88","author":[{"given":"Dolores M.","family":"Shoback","sequence":"first","affiliation":[{"name":"Department of Medicine (D.M.S.), Veterans Affairs Medical Center, University of California-San Francisco, San Francisco, California 94121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[{"name":"Department of Medicine (J.P.B.), College of Physicians and Surgeons, Columbia University, New York, New York 10032"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart A.","family":"Turner","sequence":"additional","affiliation":[{"name":"Amgen Inc. (S.A.T., L.C.M., M.D.G.), Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"McCary","sequence":"additional","affiliation":[{"name":"Amgen Inc. (S.A.T., L.C.M., M.D.G.), Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Guo","sequence":"additional","affiliation":[{"name":"Amgen Inc. (S.A.T., L.C.M., M.D.G.), Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munro","family":"Peacock","sequence":"additional","affiliation":[{"name":"Department of Medicine (M.P.), Indiana University School of Medicine, Indianapolis, Indiana 46202"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071614152539300_R1","first-page":"205","article-title":"Management of asymptomatic primary hyperparathyroidism.","volume":"2","author":"Kleerekoper","year":"1991","journal-title":"Adv Endocrinol Metab"},{"key":"2020071614152539300_R2","first-page":"183","article-title":"Immunologic assays for parathyroid hormone: principles and utilization in disease states.","volume":"2","author":"Mallette","year":"1991","journal-title":"Adv Endocrinol Metab"},{"key":"2020071614152539300_R3","first-page":"S9","article-title":"Consensus development conference statement","volume":"6","author":"Potts Jr","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2020071614152539300_R4","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1210\/jcem.84.7.5842-1","article-title":"Therapeutic controversies in primary hyperparathyroidism.","volume":"84","author":"Silverberg","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614152539300_R5","first-page":"3487","article-title":"Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.","volume":"81","author":"Guo","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614152539300_R6","first-page":"720","article-title":"Bones of contention: the problem of mild hyperparathyroidism.","volume":"80","author":"Marcus","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614152539300_R7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(94)90128-7","article-title":"Psychologic symptoms before and after parathyroid surgery.","volume":"96","author":"Solomon","year":"1994","journal-title":"Am J Med"},{"key":"2020071614152539300_R8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2796.1992.tb00608.x","article-title":"Increasing parathyroid hormone concentrations in untreated primary hyperparathyroidism.","volume":"232","author":"Rudnicki","year":"1992","journal-title":"J Intern Med"},{"key":"2020071614152539300_R9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1152\/physrev.1991.71.2.371","article-title":"Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers.","volume":"71","author":"Brown","year":"1991","journal-title":"Physiol Rev"},{"key":"2020071614152539300_R10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/366575a0","article-title":"Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid.","volume":"366","author":"Brown","year":"1993","journal-title":"Nature"},{"key":"2020071614152539300_R11","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/ki.1996.152","article-title":"A cloned extracellular Ca(2+)-sensing receptor: molecular mediator of the actions of extracellular Ca2+ on parathyroid and kidney cells?","volume":"49","author":"Brown","year":"1996","journal-title":"Kidney Int"},{"key":"2020071614152539300_R12","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","article-title":"Calcimimetics with potent and selective activity on the parathyroid calcium receptor.","volume":"95","author":"Nemeth","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 2","key":"2020071614152539300_R13","first-page":"N2","article-title":"Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century","volume":"17","author":"Bilezikian","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2020071614152539300_R14","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199711203372104","article-title":"Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism.","volume":"337","author":"Silverberg","year":"1997","journal-title":"N Engl J Med"},{"key":"2020071614152539300_R15","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1999.14.10.1700","article-title":"Primary hyperparathyroidism and the risk of fracture: a population-based study.","volume":"14","author":"Khosla","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2020071614152539300_R16","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJM199910213411701","article-title":"A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.","volume":"341","author":"Silverberg","year":"1999","journal-title":"N Engl J Med"},{"key":"2020071614152539300_R17","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJM198606053142304","article-title":"Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women.","volume":"314","author":"Selby","year":"1986","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"2020071614152539300_R18","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1002\/jbmr.5650061426","article-title":"Estrogens and progestins in the management of primary hyperparathyroidism","volume":"6","author":"Marcus","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2020071614152539300_R19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","article-title":"Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.","volume":"16","author":"Rossini","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"2020071614152539300_R20","first-page":"S226","article-title":"A double blind randomized placebo controlled trial of alendronate in primary hyperparathyroidism","volume":"16","author":"Khan","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2020071614152539300_R21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00019616-200111000-00006","article-title":"Alendronate therapy of primary hyperparathyroidism.","volume":"11","author":"Hassani","year":"2001","journal-title":"Endocrinologist"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/88\/12\/5644\/9059857\/jcem5644.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/88\/12\/5644\/9059857\/jcem5644.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T11:54:11Z","timestamp":1734177251000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/88\/12\/5644\/2661458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,1]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2002-021597","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,1]]}}}